menu
    • menu
    [{"orgOrder":0,"company":"Rentschler Biopharma","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Rentschler Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Rentschler Biopharma \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Rentschler Biopharma \/ BioNTech"},{"orgOrder":0,"company":"Rentschler Biopharma","sponsor":"Ikarovec","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Rentschler Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Rentschler Biopharma \/ Rentschler Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Rentschler Biopharma \/ Rentschler Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Rentschler Biopharma

    Menu

    Rentschler Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rentschler Biopharma

                            Germany arrow
                            American Pharma Summit
                            Not Confirmed

                            Rentschler Biopharma

                            Germany arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-based Gene Therapy

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Recipient : Ikarovec

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Rentschler Biopharma Joins Forces with Ikarovec to Accelerate Novel Gene Therapies for Treatment of Ophthalmic...

                            Details : Under the agreement, Rentschler Biopharma’s ATMP site will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel AAV-based therapy for the treatment of geographic atrophy.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 01, 2023

                            Lead Product(s) : AAV-based Gene Therapy

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Recipient : Ikarovec

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rentschler Biopharma

                            Germany arrow
                            American Pharma Summit
                            Not Confirmed

                            Rentschler Biopharma

                            Germany arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNT162

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : BioNTech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Joining forces against SARS-CoV-2, Rentschler Biopharma contributes to manufacturing of COVID-19 mRNA vaccine

                            Details : Rentschler Biopharma will be responsible for key aspects of cGMP drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial.

                            Brand Name : BNT162

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 07, 2020

                            Lead Product(s) : BNT162

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : BioNTech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth